Other trials are evaluating the safety and efficacy of second- and third-generation ALK inhibitors alone or in combination with chemotherapy and molecularly targeted compounds in patients with NB and other ALK-driven cancers (Table 1). The gene discussed is ALK; the disease is cancer.